Skip to Content

Improved OS in newly diagnosed multiple myeloma patients not eligible for stem cell transplantation

5-year data from the MAIA study show that the addition of daratumumab to lenalidomide and dexamethasone significantly reduced the risk of death in patients with newly diagnosed multiple myeloma where transplantation is not possible. The risk of death was reduced by 32% compared with lenalidomide and dexamethasone alone.

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top